Supplemental Online Content

Doan C, Li S, Goodwin JS. Breast and lung cancer screening among Medicare enrollees during the COVID-19 pandemic. *JAMA Network Open.* 2023;6(2):e2255589. doi:10.1001/jamanetworkopen.2022.55589

- **eFigure 1.** Cohort selection for mammogram rates
- **eFigure 2.** Cohort selection for low dose computed tomography rates
- eTable 1. Patient characteristics for the mammography cohort for 2017 to 2021
- **eTable 2.** Patient characteristics for the low dose computed tomography (LDCT) cohort from 2018 (March 2017-Feb 2018) to 2021 (March 2021-Feb 2022)
- **eTable 3.** Percentage of Medicare enrollees enrolled in HMO during 2017 through 2022, using 100% Medicare data in January for each year, by enrollee characteristics
- **eTable 4.** Logistic regression model using cohorts from 2017-2019 to predict the expected mammogram rate in March 2020 to February 2021
- **eTable 5.** Logistic regression model using cohorts from 2017-2019 to predict the expected LDCT rate in March 2020 to February 2021
- eTable 6. Stratified analysis for beneficiaries aged <65
- **eTable 7.** Stratified analysis for beneficiaries aged ≥65
- **eTable 8.** Stratified analysis for beneficiaries aged <65
- **eTable 9.** Stratified analysis for beneficiaries aged ≥65
- eTable 10. Stratified analysis for Medicaid beneficiaries
- eTable 11. Stratified analysis for non-Medicaid beneficiaries
- eTable 12. Stratified analysis for Medicaid beneficiaries
- eTable 13. Stratified analysis for non-Medicaid beneficiaries

This supplemental material has been provided by the authors to give readers additional information about their work.

Supplementary eFigure 1. Cohort selection for mammogram rates.

1) Choose all female beneficiaries who alive as of March 1st in each year, age between 50 and 74.

N=4,105,930 (100%) 2017

N=4,241,886 (100%) 2018

N=4,348,051 (100%) 2019

N=4,449,120 (100%) 2020

N=4,525,374 (100%) 2021



2) Keep the beneficiaries who have part A and B and no HMO during 1 year prior to March 1st and 1 year after

N=1,710,748 (41.67%) 2017

N=1,708,973 (40.29%) 2018

N=1,695,332 (38.99%) 2019

N=1,664,249 (37.41%) 2020

N=1,609,417 (35.56%) 2021

Supplementary eFigure 2. Cohort selection for low dose computed tomography rates. HMO: health maintenance organization.

1) Choose all beneficiaries who alive as of March 1st in each year, age between 55 and 79.

N=8,449,695 (100%) 2017

N=8,784,886 (100%) 2018

N=9,092,209 (100%) 2019

N=9,374,593 (100%) 2020

N=9,584,406 (100%) 2021



2) Keep the beneficiaries who have part A and B and no HMO during 1 year prior to March 1st and 1 year after

N=3,875,754 (45.87%) 2017

N=3,898,228 (44.37%) 2018

N=3,883,897 (42.72%) 2019

N=3,835,272 (40.91%) 2020

N=3,719,971 (38.81%) 2021

Supplementary eTable 1. Patient characteristics for the mammography cohort for 2017 to 2021.

| | March 2017-Feb 2018 | March 2018-Feb 2019 | March 2019-Feb 2020 | March 2020-Feb 2021 | March 2021-Feb 2022 |
|------------------------|---------------------|---------------------|---------------------|---------------------|---------------------|
| All | 1,710,748 | 1,708,973 | 1,695,332 | 1,664,249 | 1,609,417 |
| Age, years | | | | | |
| 50-65 | 331,680 (19.39%) | 313,215 (18.33%) | 287,082 (16.93%) | 256,399 (15.41%) | 223,032 (13.86%) |
| 66-70 | 857,556 (50.13%) | 853,145 (49.92%) | 838,723 (49.47%) | 817,991 (49.15%) | 778,436 (48.37%) |
| 71-74 | 521,512 (30.48%) | 542,613 (31.75%) | 569,527 (33.59%) | 589,859 (35.44%) | 607,949 (37.77%) |
| Race | | | | | |
| Black | 163,876 (9.58%) | 158,447 (9.27%) | 149,827 (8.84%) | 137,413 (8.26%) | 122,910 (7.64%) |
| Hispanic | 95,903 (5.61%) | 94,951 (5.56%) | 92,534 (5.46%) | 89,732 (5.39%) | 84,877 (5.27%) |
| White | 1,359,092 (79.44%) | 1,357,595 (79.44%) | 1,349,745 (79.62%) | 1,331,378 (80.00%) | 1,295,767 (80.51%) |
| Other ^a | 91,877 (5.37%) | 97,980 (5.73%) | 103,226 (6.09%) | 105,726 (6.35%) | 105,863 (6.58%) |
| Medicaid | | | | | |
| No | 1,389,689 (81.23%) | 1,404,176 (82.16%) | 1,414,547 (83.44%) | 1,410,852 (81.77%) | 1,385,133 (86.06%) |
| Yes | 321,059 (18.77%) | 304,797 (17.84%) | 280,785 (16.56%) | 253,397 (15.23%) | 224,284 (13.94%) |
| PCP | | | | | |
| No | 1,134,367 (66.31%) | 1,158,765 (67.80%) | 1,177,032 (69.43%) | 1,179,111 (70.85%) | 21,241,617 (77.15%) |
| Yes | 576,381 (33.69%) | 550,208 (32.20%) | 518,300 (30.57%) | 485,138 (29.15%) | 367,800 (22.85%)b |
| AHRQ comorbidity score | | | | | |
| <0 | 587,968 (34.37%) | 607,827 (35.22%) | 607,345 (35.82%) | 599,865 (36.04%) | 530,126 (32.94%) |
| 0 | 750,489 (43.87%) | 736,962 (43.12%) | 723,740 (42.69%) | 707,071 (42.49%) | 753,420 (46.81%) |
| >= | 372,291 (21.76%) | 370,184 (21.66%) | 364,247 (21.49%) | 357,313 (21.47%) | 325,871 (20.25%) |

PCP: Primary care provider; AHRQ: Agency for Healthcare Research and Quality.

^aOther race incudes American Indian/Alaskan native, Asian/Pacific Islanders, and other.

^bThe decrease in percentage of subjects with an identifiable PCP in the 2021 cohort may be an artifact of the method of assessing PCPs, which is to examine the prior 12 months of data. For the 2021 cohorts, the prior 12 months included the first 10 months of the COVID pandemic, when regular ambulatory care was substantially disrupted.⁴

Supplementary eTable 2. Patient characteristics for the LDCT cohort from 2018 (March 2017-Feb 2018) to 2021 (March 2021-Feb 2022).

| | March 2017-Feb 2018 | March 2018-Feb 2019 | March 2019-Feb 2020 | March 2020-Feb 2021 | March 2021-Feb 2022 |
|-------------------|---------------------|---------------------|---------------------|---------------------|---------------------|
| All | 3,875,754 | 3,898,228 | 3,883,897 | 3,835,272 | 3,719,971 |
| Age, years | | | | | |
| 55-65 | 510,086 (13.16%) | 489,261 (12.55%) | 454,202 (11.69%) | 410,365 (10.70%) | 359,436 (9.66%) |
| 66-70 | 1,540,109 (39.74%) | 1,525,813 (39.14%) | 1,493,768 (38.46%) | 1,453,807 (37.91%) | 1,385,791 (37.25%) |
| 71-75 | 1,137,032 (29.34%) | 1,194,865 (30.65%) | 1,231,248 (31.70%) | 1,256,900 (32.77%) | 1,271,074 (34.17%) |
| 76-79 | 688,527 (17.76%) | 688,289 (17.66%) | 704,679 (18.14%) | 714,200 (18.62%) | 703,670 (18.92%) |
| Sex | | | | | |
| Male | 1,779,908 (45.92%) | 1,787,343 (45.85%) | 1,776,643 (45.74%) | 1,750,617 (45.65%) | 1,692,459 (45.50%) |
| Female | 2,095,846 (54.08%) | 2,110,885 (54.15%) | 2,107,254 (54.26%) | 2,084,655 (54.35%) | 2,027,512 (54.50%) |
| Race | | | | | |
| Black | 323,766 (8.35%) | 316,623 (8.12%) | 302,473 (7.79%) | 280,717 (7.32%) | 251,921 (6.77%) |
| Hispanic | 203,321 (5.25%) | 202,709 (5.20%) | 198,492 (5.11%) | 194,044 (5.06%) | 184,225 (4.95%) |
| White | 3,132,154 (80.81%) | 3,147,797 (80.75%) | 3,140,012 (80.85%) | 3,110,315 (81.10%) | 3,032,100 (81.51%) |
| Othera | 216,513 (5.59%) | 231,099 (5.93%) | 242,920 (6.25%) | 250,196 (6.52%) | 251,725 (6.77%) |
| Medicaid | | | | | |
| No | 3,313,064 (85.48%) | 3,354,348 (86.05%) | 3,372,481 (86.83%) | 3,362,908 (87.68%) | 3,295,732 (88.60%) |
| Yes | 562,690 (14.52%) | 543,880 (13.95%) | 511,416 (13.17%) | 472,364 (12.32%) | 424,239 (11.40%) |
| PCP | | | | | |
| No | 2,590,533 (66.84%) | 2,656,190 (68.14%) | 2,700,860 (69.54%) | 2,712,106 (70.71%) | 2,864,461 (77.00%) |
| Yes | 1,284,821 (33.15%) | 1,242,038 (31.86%) | 1,183,037 (30.46%) | 1,123,166 (29.29%) | 855,510 (23.00%)b |
| AHRQ | , | , | , | · · | , |
| comorbidity score | | | | | |
| <0 | 1,059,573 (27.34%) | 1,101,063 (28.25%) | 1,130,634 (29.11%) | 1,129,729 (29.46%) | 1,005,999 (27.04%) |
| 0 | 1,794,636 (46.30%) | 1,761,198 (45.18%) | 1,723,998 (44.39%) | 1,679,954 (43.80%) | 1,774,451 (47.70%) |
| >0 | 1,021,545 (26.36%) | 1,032,967 (26.50%) | 1,029,265 (26.50%) | 1,025,589 (26.74%) | 939,521 (25.26%) |

LDCT: low dose computed tomography; PCP: Primary care provider; AHRQ: Agency for Healthcare Research and Quality. aOther race incudes American Indian/Alaskan native, Asian/Pacific Islanders, and other.

^bThe decrease in percentage of subjects with an identifiable PCP in the 2021 cohort may be an artifact of the method of assessing PCPs, which is to examine the prior 12 months of data. For the 2021 cohorts, the prior 12 months included the first 10 months of the COVID pandemic, when regular ambulatory care was substantially disrupted.⁴

Supplementary eTable 3. Percentage of Medicare enrollees enrolled in a Health Maintenance Organization (HMO) during 2017 through 2021, using 100% Medicare data in January for each year, by enrollee characteristics.

| | | Percentage of HMO enrollment (%) | | | | | | | | |
|--------------------|-------|----------------------------------|-------|-------|-------|--|--|--|--|--|
| | 2017 | 2018 | 2019 | 2020 | 2021 | | | | | |
| All | 31.82 | 33.41 | 34.98 | 37.37 | 40.32 | | | | | |
| Age | | | | | | | | | | |
| <65 | 21.36 | 22.93 | 24.86 | 27.85 | 31.06 | | | | | |
| >=65 | 34.54 | 36.05 | 37.44 | 39.56 | 42.36 | | | | | |
| Sex | | | | | | | | | | |
| Male | 30.31 | 31.82 | 33.25 | 35.57 | 38.50 | | | | | |
| Female | 33.09 | 34.76 | 36.45 | 38.89 | 41.86 | | | | | |
| Medicaid | | | | | | | | | | |
| No | 31.55 | 32.91 | 34.09 | 36.01 | 38.48 | | | | | |
| Yes | 33.02 | 35.72 | 39.15 | 43.77 | 48.88 | | | | | |
| Race | | | | | | | | | | |
| Black | 29.55 | 30.98 | 32.35 | 34.53 | 37.30 | | | | | |
| Hispanic | 36.15 | 38.78 | 41.34 | 44.90 | 49.53 | | | | | |
| White | 46.41 | 47.97 | 49.76 | 52.25 | 54.77 | | | | | |
| Other ^a | 29.73 | 31.23 | 32.84 | 35.06 | 37.73 | | | | | |

^aOther race incudes American Indian/Alaskan native, Asian/Pacific Islanders, and other.

Supplementary eTable 4. Logistic regression model using cohorts from 2017-2019 to predict the expected mammogram rate in March 2020 to February 2021. The 95% confidence interval (CI) for expected rate was calculated using the bootstrap method with 30 runs.

| | Expected Mammogram rate (95% CI) | Observed Mammogram rate | O/E ratio (95% CI) |
|--------------------|----------------------------------|-------------------------|--------------------|
| All | 47.85% (47.82%, 47.88%) | 39.53% | 0.83 (0.82, 0.83) |
| Age, years | | | |
| 50-65 | 36.09% (36.06%, 36.12%) | 27.50% | 0.76 (0.76, 0.76) |
| 66-70 | 50.71% (50.68%, 50.74%) | 42.31% | 0.83 (0.83, 0.84) |
| 71-74 | 49.00% (48.96%, 83.55%) | 40.91% | 0.83 (0.83, 0.84) |
| Race | | | |
| Black | 45.40% (45.36%, 45.45%) | 37.15% | 0.82 (0.81, 0.82) |
| Hispanic | 39.17% (39.11%, 39.23%) | 29.29% | 0.75 (0.74, 0.75) |
| White | 48.89% (48.86%, 48.92%) | 40.83% | 0.84 (0.83, 0.84) |
| Other ^a | 45.31% (45.26%, 45.35%) | 34.96% | 0.77 (0.77, 0.78) |
| Medicaid | | | |
| No | 50.54% (50.51%, 50.57%) | 42.45% | 0.84 (0.83, 0.84) |
| Yes | 32.88% (32.85%, 32.91%) | 23.26% | 0.71 (0.70, 0.71) |
| PCP | | | |
| No | 45.93% (45.89%, 45.96%) | 37.72% | 0.82 (0.82, 0.83) |
| Yes | 52.53% (52.49%, 52.57%) | 43.94% | 0.84 (0.84, 0.84) |
| Comorbidity score | | | |
| <0 | 51.24% (51.21%, 51.28%) | 42.60% | 0.83 (0.83, 0.83) |
| 0 | 46.90% (46.86%, 46.93%) | 38.26% | 0.82 (0.82, 0.83) |
| >0 | 44.05% (44.01%, 44.09%) | 36.89% | 0.84 (0.84, 0.85) |

O/E: observed/expected; PCP: Primary care provider.

^aOther race incudes American Indian/Alaskan native, Asian/Pacific Islanders, and other.

Supplementary eTable 5. Logistic regression model using cohorts from 2017-2019 to predict the expected LDCT rate in March 2020 to February 2021. The 95% confidence interval (CI) for expected rate was calculated using the bootstrap method with 30 runs.

| | Expected LDCT rate per 1,000,000 (95% CI) | Observed LDCT rate per 1,000,000 | O/E ratio (95% CI) |
|-------------------|---|----------------------------------|--------------------|
| All | 16,436 (16,402, 16,471) | 11,411 | 0.69 (0.69, 0.70) |
| Age, years | | | |
| 55-65 | 28,832 (28,986, 28,965) | 19,690 | 0.68 (0.68, 0.69) |
| 66-70 | 19,380 (19,349, 19,424) | 13,383 | 0.69 (0.68, 0.69) |
| 71-75 | 15,428 (15,388, 15,467) | 10,670 | 0.69 (0.68, 0.69) |
| 76-79 | 5,097 (5,062, 5,131) | 3,944 | 0.77 (0.77, 0.78) |
| Sex | | | |
| Male | 18,214 (18,161, 18,266) | 12,790 | 0.70 (0.70, 0.71) |
| Female | 14,944 (14,910, 14,977) | 10,253 | 0.69 (0.68, 0.69) |
| Race | | | |
| Black | 11,945 (11,893, 11,998) | 7,983 | 0.67 (0.66, 0.67) |
| Hispanic | 6,787 (6,720, 6,854) | 4,174 | 0.62 (0.61, 0.62) |
| White | 17,955 (17,915, 17,996) | 12,513 | 0.70 (0.69, 0.70) |
| Othera | 10,074 (10,030, 10,145) | 7,178 | 0.71 (0.71, 0.72) |
| Medicaid | | | |
| No | 15,520 (15,487, 15,553) | 10,886 | 0.70 (0.70, 0.71) |
| Yes | 22,958 (22,885, 23,030) | 15,154 | 0.66 (0.65, 0.66) |
| PCP | | | |
| No | 15,140 (15,103, 15,176) | 10,480 | 0.69 (0.69, 0.70) |
| Yes | 19,567 (19,510, 19,624) | 13,632 | 0.70 (0.69, 0.70) |
| Comorbidity score | | | |
| <0 | 18,768 (18,722, 18,814) | 13,133 | 0.70 (0.69, 0.70) |
| 0 | 11,229 (11,193, 11,265) | 7,234 | 0.64 (0.64, 0.65) |
| >0 | 22,397 (22,336, 22,458) | 16,357 | 0.73 (0.73, 0.73) |

LDCT: low dose computed tomography; O/E: observed/expected; PCP: PCP: Primary care provider.

^aOther race includes American Indian/Alaskan native, Asian/Pacific Islanders, and other.

Supplementary eTable 6. Expected and observed mammogram rates for enrollees aged >50 to <65 years for 3/20 to 2/21 and 3/21 to 2/22 from a prediction model using 2017-2019 cohorts, with a linear probability model for each sub-cohort, with year as the only variable in the models.

| | 3/20 to 2/21 | | | 3/21 to 2/22 | | |
|--------------------|-------------------------------------|----------------------------------|--------------------|-------------------------------------|----------------------------------|--------------------|
| Enrollees (<65) | Expected Mammogram rate, % (95% CI) | Observed Mammogram rate, % | O/E ratio (95% CI) | Expected Mammogram rate, % (95% CI) | Observed Mammogram rate, % | O/E ratio (95% CI) |
| All | 33.54 (33.26-33.82) | 26.09 | 0.78 (0.77-0.78) | 33.85 (33.45-34.25) | 31.22 | 0.92 (0.91-0.93) |
| Race | | | | | | |
| Black | 37.01 (36.33-37.68) | 29.62 | 0.80 (0.79-0.82) | 37.24 (36.28-38.20) | 34.24 | 0.92 (0.90-0.94) |
| Hispanic | 35.12 (34.14-36.10) | 26.44 | 0.75 (0.73-0.77) | 35.48 (34.08-36.87) | 31.41 | 0.89 (0.85-0.92) |
| White | 32.55 (32.21-32.88) | 25.36 | 0.78 (0.77-0.79) | 32.90 (32.42-33.37) | 30.60 | 0.93 (0.89-0.92) |
| Othera | 32.29 (30.87-33.70) | 22.92 | 0.71 (0.68-0.74) | 32.54 (30.51-34.56) | 29.20 | 0.90 (0.84-0.96) |
| Medicaid | | | | | | |
| No | 33.87 (33.46-34.27) | 26.99 | 0.80 (0.79-0.81) | 34.27 (33.69-34.84) | 32.22 | 0.94 (0.92-0.96) |
| Yes | 33.24 (32.85-33.62) | 25.22 | 0.76 (0.75-0.77) | 33.46 (32.91-34.02) | 30.21 | 0.90 (0.89-0.92) |
| PCP | | | | | | |
| No | 30.59 (30.25-30.92) | 23.56 | 0.77 (0.76-0.79) | 30.84 (30.36-31.32) | 29.14 | 0.95 (0.93-0.96) |
| Yes | 40.23 (39.72-40.73) | 31.94 | 0.79 (0.78-0.80) | 41.11 (40.39-41.83) | 37.58 | 0.91 (0.90-0.93) |
| Comorbidity | | | | | | |
| score | | | | | | |
| <0 | 38.18 (37.77-38.59) | 29.87 | 0.78 (0.77-0.79) | 38.76 (38.17-39.35) | 35.81 | 0.92 (0.91-0.94) |
| 0 | 26.15 (25.63-26.68) | 19.74 | 0.75 (0.74-0.77) | 25.85 (25.10-26.59) | 24.67 | 0.95 (0.93-0.98) |
| >0 | 31.78 (31.24-32.32) | 25.09 | 0.79 (0.78-0.80) | 32.00 (31.22-32.77) | 30.33 | 0.95 (0.93-0.97) |

^aOther includes Asian/pacific islander, American Indian/Alaska native or others. O/E: observed/expected; CI: Confidence Interval; PCP: Primary care provider.

Supplementary eTable 7. Stratified analysis for beneficiaries aged >=65. Expected and observed mammogram rates for enrollees aged ≥65 years for 3/20 to 2/21 and 3/21 to 2/22 from a prediction model using 2017-2019 cohorts, with a linear probability model for each sub-cohort, with year as the only variable in the models.

| Age 65-74 | Expected Mammogram rate, % (95% CI) | Observed Mammogram rate, % | O/E ratio (95% CI) | Expected Mammogram rate, % (95% CI) | Observed Mammogram rate, % | O/E ratio (95% CI) |
|-------------|-------------------------------------|----------------------------------|--------------------|-------------------------------------|----------------------------------|--------------------|
| All | 50.03 (49.90-50.15) | 41.56 | 0.83 (0.82-0.83) | 51.10 (50.92-51.28) | 49.22 | 0.96 (0.96-0.97) |
| Race | | | | | | |
| Black | 47.54 (47.09-48.00) | 40.02 | 0.84 (0.83-0.85) | 48.53 (47.87-49.18) | 47.05 | 0.97 (0.96-0.98) |
| Hispanic | 39.15 (38.61-39.69) | 30.05 | 0.77 (0.76-0.78) | 39.82 (39.04-40.59) | 37.40 | 0.94 (0.92-0.96) |
| White | 51.19 (51.06-51.33) | 42.84 | 0.84 (0.83-0.84) | 52.30 (52.10-52.50) | 50.36 | 0.96 (0.96-0.97) |
| Othera | 46.56 (46.07-47.05) | 36.04 | 0.77 (0.77-0.78) | 47.71 (47.00-48.43) | 46.01 | 0.97 (0.95-0.98) |
| Medicaid | | | | | | |
| No | 52.23 (52.10-52.36) | 43.73 | 0.84 (0.83-0.84) | 53.27 (53.08-53.46) | 51.39 | 0.96 (0.96-0.97) |
| Yes | 30.31 (29.96-30.65) | 21.73 | 0.72 (0.71-0.73) | 30.51 (30.02-31.01) | 27.68 | 0.91 (0.89-0.92) |
| PCP | | | | | | |
| No | 48.17 (48.02-48.32) | 39.83 | 0.83 (0.82-0.83) | 49.31 (49.09-49.52) | 47.94 | 0.97 (0.97-0.98) |
| Yes | 54.59 (54.36-54.81) | 45.82 | 0.84 (0.83-0.84) | 55.81 (55.49-56.14) | 53.61 | 0.96 (0.95-0.97) |
| Comorbidity | | | | | | |
| score | | | | | | |
| <0 | 54.56 (54.34-54.78) | 45.36 | 0.83 (0.83-0.84) | 55.86 (55.56-56.18) | 53.62 | 0.96 (0.95-0.97) |
| 0 | 48.38 (48.20-48.56) | 39.82 | 0.82 (0.82-0.83) | 49.23 (48.97-49.50) | 47.71 | 0.97 (0.96-0.97) |
| >0 | 46.06 (45.78-46.33) | 39.12 | 0.85 (0.84-0.85) | 46.99 (46.60-47.38) | 46.02 | 0.98 (0.97-0.99) |

^aOther includes Asian/Pacific Islander, American Indian/Alaska native, or others.

CI: confidence interval; O/E ratio: observed/expected ratio; PCP: primary care provider.

Supplementary eTable 8. Stratified analysis for beneficiaries aged <65. Expected and observed LDCT rates for 3/20 to 2/21 and 3/21 to 2/22 from a prediction model using 2017-2019 cohorts, with a linear probability model for each sub-cohort, with year as the only variable in the models.

| Age <65 | 3/20 to 2/21 | | | 3/21 to 2/22 | | | |
|-------------|---|----------------------------------|--------------------|---|--------------------|--------------------|--|
| | Expected LDCT rate per 1,000,000 (95% CI) | Observed LDCT rate per 1,000,000 | O/E ratio (95% CI) | Expected LDCT rate per 1,000,000 (95% CI) | Observed LDCT rate | O/E ratio (95% CI) | |
| All | 27,391 (26,727-28,055) | 20,246 | 0.74 (0.72-0.76) | 32,573 (31,640-33,506) | 26,403 | 0.81 (0.79-0.83) | |
| Sex | | | | | | | |
| Male | 25,757 (24,851-26,663) | 18,908 | 0.73 (0.71-0.86) | 30,594 (29,322-31,866) | 24,874 | 0.81 (0.78-0.85) | |
| Female | 29,083 (28,107-30,059) | 21,654 | 0.75 (0.72-0.77) | 34,629 (33,357-35,901) | 28,024 | 0.81 (0.78-0.84) | |
| Race | | | | | | | |
| Black | 13,927 (12,737-15,118) | 9,603 | 0.69 (0.64-0.75) | 16,129 (14,453-17,805) | 14,485 | 0.90 (0.81-1.02) | |
| Hispanic | 9,140 (7,743-10,537) | 7,114 | 0.78 (0.68-0.92) | 10,704 (8,734-12,674) | 9,510 | 0.89 (0.75-1.01) | |
| White | 33,381 (32,515-34,247) | 24,785 | 0.74 (0.72-0.76) | 39,812 (38,595-41,029) | 31,689 | 0.80 (0.77-0.82) | |
| Othera | 15,454 (12,896-18,012) | 10,753 | 0.70 (0.60-0.83) | 18,418 (14,821-22,015) | 15,053 | 0.82 (0.68-1.02) | |
| Medicaid | | | | | | | |
| No | 23,769 (22,926-24,612) | 17,770 | 0.75 (0.72-0.78) | 28,290 (27,108-29,472) | 23,690 | 0.84 (0.80-0.87) | |
| Yes | 31,724 (30,666-32,782) | 23,281 | 0.73 (0.71-0.76) | 37,700 (36,216-39,184) | 29,762 | 0.79 (0.76-0.82) | |
| PCP | | | | | | | |
| No | 25,003 (24,250-25,756) | 17,892 | 0.72 (0.69-0.74) | 29,863 (28,808-30,918) | 24,644 | 0.83 (0.80-0.86) | |
| Yes | 33,441 (32,087-34,795) | 26,478 | 0.79 (0.76-0.83) | 39,622 (37,727-41,517) | 32,633 | 0.82 (0.79-0.86) | |
| Comorbidity | | | | | | | |
| score | | | | | | | |
| <0 | 33,417 (32,266-34,568) | 25,027 | 0.75 (0.72-0.78) | 39,834 (38,219-41,449) | 33,152 | 0.83 (0.80-0.87) | |
| 0 | 17,030 (16,081-17,987) | 11,708 | 0.69 (0.65-0.73) | 20,111 (18,772-21,450) | 17,514 | 0.87 (0.82-0.93) | |
| >0 | 29,917 (28,609-31,225) | 22,642 | 0.76 (0.73-0.79) | 35,451 (33,615-37,287) | 28,179 | 0.79 (0.76-0.84) | |

^aOther includes Asian/pacific islander, American Indian/Alaska native or others O/E: observed/expected; CI: Confidence Interval; PCP: Primary care provider.

Supplementary eTable 9. Stratified analysis for beneficiary aged >=65. Expected and observed low dose computed tomography (LDCT) rates for 3/20 to 2/21 and 3/21 to 2/22 from a prediction model using 2017-2019 cohorts, with a linear probability model for each sub-cohort, with year as the only variable in the models.

| Age >=65 | Expected LDCT rate per | Observed LDCT | O/E ratio (95% CI) | Exp ected LDCT rate per | Observed | O/E ratio (95% CI) |
|-------------|------------------------|--------------------|--------------------|-------------------------|-----------|--------------------|
| | 1,000,000 (95% CI) | rate per 1,000,000 | , , | 1,000,000 (95% CI) | LDCT rate | , , , |
| All | 13,628 (13,467-13,787) | 10,553 | 0.77 (0.77-0.78) | 16,132 (15,909-16,356) | 14,237 | 0.88 (0.87-0.89) |
| Sex | | | | | | |
| Male | 15,449 (15,200-15,698) | 12,115 | 0.78 (0.77-0.80 | 18,292 (17,941-18,643) | 16,130 | 0.88 (0.87-0.90) |
| Female | 12,133 (12,335-11,931) | 9,270 | 0.76 (0.75-0.78) | 14,345 (14,629-14,061) | 12,690 | 0.88 (0.87-0.90) |
| Race | | | | | | |
| Black | 9,894 (9,382-10,406) | 7,586 | 0.77 (0.73-0.81) | 11,746 (11,025-12,467) | 10,582 | 0.90 (0.85-0.96) |
| Hispanic | 5,301 (4,843-5,759) | 3,662 | 0.69 (0.64-0.76) | 6,228 (5,581-6,874) | 5,884 | 0.94 (0.86-1.05) |
| White | 14,787 (14,605-14,969) | 12,176 | 0.82 (0.81-0.83) | 17,512 (17,255-17,769) | 15,354 | 0.88 (0.86-0.90) |
| Othera | 9,028 (8,522-9,534) | 6,972 | 0.77 (0.73-0.82) | 10,747 (10,032-11,462) | 9,762 | 0.91 (0.85-0.97) |
| Medicaid | | | | | | |
| No | 13,387 (13,222-13,552) | 10,480 | 0.78 (0.77-0.79) | 15,841 (15,608-16,074) | 14,070 | 0.89 (0.88-0.90) |
| Yes | 15,883 (15,344-16,422) | 11,278 | 0.71 (0.69-0.74) | 18,904 (18,147-19,661) | 16,026 | 0.85 (0.82-0.88) |
| PCP | | | | | | |
| No | 12,601 (12,419-12,783) | 9,752 | 0.77 (0.76-0.79) | 14,968 (14,711-15,225) | 13,582 | 0.91 (0.85-0.92) |
| Yes | 16,013 (15,705-16,321) | 12,471 | 0.78 (0.76-0.79) | 18,902 (18,469-19,335) | 16,420 | 0.87 (0.85-0.89) |
| Comorbidity | | | | | | |
| score | | | | | | |
| <0 | 14,687 (14,375-14,999) | 11,478 | 0.78 (0.77-0.80) | 17,392 (16,951-17,833) | 15,776 | 0.91 (0.88-0.93) |
| 0 | 9,520 (9,324-9,716) | 6,937 | 0.73 (0.71-0.74) | 11,217 (10,941-11,493) | 10,155 | 0.91 (0.88-0.93) |
| >0 | 19,574 (19,206-19,942) | 15,703 | 0.80 (0.79-0.82) | 23,157 (22,638-23,676) | 20,584 | 0.89 (0.87-0.91) |

^aOther includes Asian/Pacific Islander, American Indian/Alaska native, or others.

CI: confidence interval; O/E ratio: observed/expected ratio; PCP: primary care provider.

Supplementary eTable 10. Stratified analysis for Medicaid beneficiaries. Expected and observed mammogram rates for 3/20 to 2/21 and 3/21 to 2/22 from a prediction model using 2017-2019 cohorts, with a linear probability model for each subcohort, with year as the only variable in the models.

| | 3/20 to 2/21 | | | 3/21 to 2/22 | | |
|-----------------------|-------------------------------------|-------------------------------|--------------------|-------------------------------------|----------------------------------|--------------------|
| Medicaid Enrollees | Expected Mammogram rate, % (95% CI) | Observed Mammogram rate, % | O/E ratio (95% CI) | Expected Mammogram rate, % (95% CI) | Observed Mammogram rate, % | O/E ratio (95% CI) |
| All | 31.61 (31.35-31.87) | 23.26 | 0.74 (0.73-0.74) | 31.80 (31.43-32.17) | 28.74 | 0.90 (0.89-0.91) |
| Age, years | | | | | | |
| 50-65 | 33.14 (32.77-33.51) | 25.18 | 0.76 (0.75-0.77) | 33.33 (32.79-33.86) | 30.17 | 0.91 (0.89-0.92) |
| 66-74 | 30.20 (29.85-30.56) | 21.54 | 0.71 (0.70-0.72) | 30.45 (29.94-30.96) | 27.55 | 0.90 (0.89-0.92) |
| Race | | | | | | |
| Black | 34.66 (34.05-35.28) | 26.91 | 0.78 (0.76-0.79) | 34.60 (33.72-35.48) | 31.64 | 0.91 (0.89-0.94) |
| Hispanic | 34.95 (34.22-35.67) | 24.77 | 0.71 (0.69-0.72) | 35.13 (34.08-36.17) | 31.14 | 0.89 (0.86-0.91) |
| White | 29.88 (29.55-30.21) | 22.26 | 0.74 (0.74-0.75) | 30.14 (29.68-30.61) | 27.18 | 0.90 (0.89-0.92) |
| Othera | 32.06 (31.16-32.97) | 20.44 | 0.64 (0.62-0.66) | 32.28 (30.98-33.58) | 29.82 | 0.92 (0.89-0.96) |
| PCP | | | | | | |
| No | 28.67 (28.36-28.98) | 20.78 | 0.72 (0.72-0.73) | 28.85 (28.41-29.30) | 26.66 | 0.92 (0.91-0.94) |
| Yes | 38.03 (37.57-38.49) | 28.75 | 0.76 (0.75-0.77) | 38.70 (38.04-39.35) | 35.07 | 0.91 (0.89-0.92) |
| Comorbidity | | | | | | |
| score | | | | | | |
| <0 | 36.61 (36.21-37.01) | 27.19 | 0.74 (0.73-0.75) | 37.16 (36.58-37.73) | 33.52 | 0.90 (0.89-0.92) |
| 0 | 26.87 (26.38-27.36) | 18.76 | 0.70 (0.69-0.71) | 26.55 (25.85-27.24) | 24.92 | 0.94 (0.91-0.96) |
| >0 | 28.17 (27.71-28.63) | 21.32 | 0.76 (0.74-0.77) | 28.18 (27.51-28.83) | 25.96 | 0.92 (0.90-0.94) |

^aOther includes Asian/Pacific Islander, American Indian/Alaska native, or others.

CI: confidence interval; O/E ratio: observed/expected ratio; PCP: primary care provider.

Supplementary eTable 11. Stratified analysis for non-Medicaid beneficiaries. Expected and observed mammogram rates for 3/20 to 2/21 and 3/21 to 2/22 from a prediction model using 2017-2019 cohorts, with a linear probability model for each subcohort, with year as the only variable in the models.

| Non- | Expected Mammogram | Observed | O/E ratio (95% CI) | Expected Mammogram | Observed | O/E ratio (95% CI) |
|-------------|---------------------|-----------------|--------------------|---------------------|-----------|--------------------|
| Medicaid | rate, % (95% CI) | Mammogram rate, | | rate, % (95% CI) | Mammogram | |
| Enrollees | | % | | | rate, % | |
| All | 50.80 (50.68-50.93) | 42.45 | 0.84 (0.83-0.84) | 51.90 (51.72-52.08) | 50.08 | 0.96 (0.96-0.97) |
| Age, years | | | | | | |
| 50-65 | 36.94 (36.57-37.30) | 29.54 | 0.80 (0.79-0.81) | 37.54 (37.02-38.07) | 35.36 | 0.94 (0.93-0.96) |
| 66-74 | 52.33 (52.20-52.46) | 43.84 | 0.84 (0.83-0.84) | 53.37 (53.17-53.56) | 51.49 | 0.96 (0.96-0.97) |
| Race | | | | | | |
| Black | 49.49 (49.01-49.96) | 42.06 | 0.85 (0.84-0.86) | 50.60 (49.92-51.29) | 49.03 | 0.97 (0.96-0.98) |
| Hispanic | 40.47 (39.85-41.10) | 32.22 | 0.80 (0.78-0.81) | 41.32 (40.42-42.22) | 39.32 | 0.95 (0.93-0.97) |
| White | 51.52 (51.38-51.66) | 43.20 | 0.84 (0.84-0.84) | 52.62 (52.42-52.82) | 50.75 | 0.96 (0.96-0.97) |
| Othera | 49.05 (48.51-49.59) | 38.95 | 0.79 (0.78-0.80) | 50.27 (49.49-51.05) | 48.69 | 0.97 (0.95-0.98) |
| PCP | | | | | | |
| No | 48.91 (48.76-49.06) | 40.66 | 0.83 (0.83-0.83) | 50.07 (49.85-50.29) | 48.79 | 0.97 (0.97-0.98) |
| Yes | 55.55 (55.27-55.73) | 46.88 | 0.84 (0.84-0.85) | 56.74 (56.41-57.06) | 54.53 | 0.96 (0.96-0.97) |
| Comorbidity | | | | | | |
| score | | | | | | |
| <0 | 55.12 (54.90-55.34) | 46.16 | 0.84 (0.83-0.84) | 56.43 (56.11-56.74) | 54.32 | 0.96 (0.96-0.97) |
| 0 | 48.68 (48.50-48.87) | 40.26 | 0.83 (0.82-0.83) | 49.57 (49.31-49.84) | 48.17 | 0.97 (0.97-0.98) |
| >0 | 48.04 (47.76-48.32) | 41.04 | 0.85 (0.85-0.86) | 49.00 (48.60-49.41) | 48.02 | 0.98 (0.97-0.99) |

^aOther includes Asian/Pacific Islander, American Indian/Alaska native, or others.

CI: confidence interval; O/E ratio: observed/expected ratio; PCP: primary care provider.

Supplementary eTable 12. Stratified analysis for Medicaid beneficiaries. Expected and observed low dose computed tomography (LDCT) rates for 3/20 to 2/21 and 3/21 to 2/22 from a prediction model using 2017-2019 cohorts, with a linear probability model for each sub-cohort, with year as the only variable in the models.

| Medicaid | | 3/20 to 2/21 | | 3/21 to 2/22 | | |
|-------------|------------------------|--------------------|--------------------|------------------------|-----------|--------------------|
| | Expected LDCT rate per | Observed LDCT | O/E ratio (95% CI) | Expected LDCT rate per | Observed | O/E ratio (95% CI) |
| | 1,000,000 (95% CI) | rate per 1,000,000 | | 1,000,000 (95% CI) | LDCT rate | |
| All | 21,173 (20,668-21,679) | 15,154 | 0.72 (0.70-0.73) | 25,144 (24,435-25,854) | 20,288 | 0.81 (0.78-0.83) |
| Age, years | | | | | | |
| 50-65 | 31,464 (30,455-32,473) | 23,096 | 0.73 (0.71-0.76) | 37,411 (36,001-38,821) | 29,558 | 0.79 (0.76-0.82) |
| 66-74 | 15,192 (14,651-15,733) | 10,765 | 0.71 (0.68-0.74) | 18,061 (17,301-18,821) | 15,431 | 0.85 (0.82-0.89) |
| Race | | | | | | |
| Black | 14,612 (13,591-15,633) | 9,862 | 0.67 (0.63-0.73) | 17,259 (15,834-18,684) | 13,845 | 0.80 (0.74-0.87) |
| Hispanic | 5,989 (5,243-6,735) | 4,402 | 0.74 (0.65-0.84) | 6,949 (5,895-8,003) | 6,414 | 0.92 (0.80-1.09) |
| White | 29,030 (28,262-29,798) | 21,147 | 0.73 (0.71-0.75) | 34,571 (33,490-35,651) | 27,922 | 0.81 (0.78-0.83) |
| Othera | 8,556 (7,520-9,592) | 5,531 | 0.65 (0.58-0.74) | 10,182 (8,719-11,645) | 8,375 | 0.82 (0.72-0.96) |
| Sex | | | | | | |
| Male | 22,441 (21,632-23,250) | 16,158 | 0.72 (0.69-0.75) | 26,608 (25,528-27,688) | 22,284 | 0.84 (0.80-0.87) |
| Female | 20,258 (19,611-20,905) | 14,420 | 0.71 (0.69-0.74) | 24,083 (23,176-24,990) | 18,805 | 0.78 (0.75-0.81) |
| PCP | | | | | | |
| No | 20,157 (19,561-20,753) | 14,392 | 0.71 (0.69-0.74) | 24,011 (23,172-24,850) | 19,775 | 0.82 (0.82-0.85) |
| Yes | 23,473 (22,530-22,416) | 17,160 | 0.73 (0.70-0.76) | 27,802 (26,481-29,123) | 21,965 | 0.79 (0.75-0.83) |
| Comorbidity | | | | | | |
| score | | | | | | |
| <0 | 25,388 (24,475-26,301) | 18,095 | 0.71 (0.69-0.74) | 30,193 (28,909-31,477) | 24,384 | 0.81 (0.77-0.84) |
| 0 | 14,600 (13,822-15,378) | 9,077 | 0.62 (0.59-0.66) | 17,376 (16,284-18,468) | 14,199 | 0.82 (0.77-0.87) |
| >0 | 22,143 (21,253-23,033) | 17,104 | 0.77 (0.74-0.71) | 26,154 (24,902-27,406) | 22,314 | 0.85 (0.81-0.90) |

^aOther includes Asian/Pacific Islander, American Indian/Alaska native, or others.

CI: confidence interval; O/E ratio: observed/expected ratio; PCP: primary care provider.

Supplementary eTable 13. Stratified analysis for non-Medicaid beneficiaries. Expected and observed low dose computed tomography (LDCT) rates for 3/20 to 2/21 and 3/21 to 2/22 from a prediction model using 2017-2019 cohorts, with a linear probability model for each sub-cohort, with year as the only variable in the models.

| Non- | Expected LDCT rate per | Observed LDCT | O/E ratio (95% CI) | Expected LDCT rate per | Observed | O/E ratio (95% CI) |
|-------------|------------------------|--------------------|--------------------|------------------------|-----------|--------------------|
| Medicaid | 1,000,000 (95% CI) | rate per 1,000,000 | | 1,000,000 (95% CI) | LDCT rate | |
| All | 14,008 (13,845-14,171) | 10,886 | 0.78 (0.77-0.79) | 16,567 (16,336-16,798) | 14,546 | 0.88 (0.86-0.89) |
| Age, years | | | | | | |
| 50-65 | 22,769 (22,040-23,498) | 17,326 | 0.76 (0.74-0.79) | 27,042 (26,018-28,066) | 23,063 | 0.85 (0.82-0.89) |
| 66-74 | 13,274 (13,109-13,439) | 10,386 | 0.78 (0.77-0.79) | 15,711 (15,472-15,950) | 13,956 | 0.89 (0.88-0.90) |
| Race | | | | | | |
| Black | 9,137 (8,612-9,662) | 7,259 | 0.79 (0.75-0.84) | 10,762 (10,020-11,504) | 10,398 | 0.97 (0.90-1.04) |
| Hispanic | 5,838 (5,286-6,391) | 4,044 | 0.69 (0.63-0.77) | 6,893 (6,113-7,673) | 6,376 | 0.92 (0.83-1.04) |
| White | 15,044 (14,851-15,237) | 11,677 | 0.78 (0.77-0.79) | 17,790 (17,533-18,047) | 15,479 | 0.87 (0.86-0.88) |
| Othera | 9,628 (9,055-10,202) | 7,583 | 0.79 (0.74-0.84) | 11,439 (10,632-12,247) | 10,400 | 0.91 (0.85-0.98) |
| Sex | | | | | | |
| Male | 15,752 (15,499-16,005) | 12,357 | 0.78 (0.77-0.80) | 18,639 (18,282-18,996) | 16,271 | 0.87 (0.86-0.89) |
| Female | 12,509 (12,297-12,721) | 9,625 | 0.78 (0.77-0.80) | 14,793 (14,495-15,091) | 13,085 | 0.88 (0.87-0.90) |
| PCP | | | | | | |
| No | 12,878 (12,690-13,066) | 9,961 | 0.77 (0.76-0.78) | 15,293 (15,028-15,558) | 13,791 | 0.90 (0.89-0.92) |
| Yes | 16,677 (16,354-17,000) | 13,127 | 0.79 (0.77-0.80) | 19,663 (19,208-20,118) | 17,082 | 0.87 (0.85-0.90) |
| Comorbidity | | | | | | |
| score | | | | | | |
| <0 | 15,570 (15,243-15,897) | 12,241 | 0.79 (0.77-0.80) | 18,409 (17,944-18,874) | 16,616 | 0.90 (0.88-0.93) |
| 0 | 9,592 (9,392-9,792) | 7,071 | 0.74 (0.72-0.75) | 11,289 (11,009-11,569) | 10,260 | 0.91 (0.89-0.93) |
| >0 | 20,333 (19,943-20,723) | 16,215 | 0.80 (0.78-0.81) | 24,050 (23,499-24,601) | 21,046 | 0.88 (0.86-0.90) |

at Other includes Asian/Pacific Islander, American Indian/Alaska native, or others.

CI: confidence interval; O/E ratio: observed/expected ratio; PCP: primary care provider.